Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSharp Therapeutics Corp.

Sharp Therapeutics Corp.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.37 CAD 0.00(0%)
Last update at 2026-11-03T14:30:00Z
Market Cap
63.16M

Momentum Score

…

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.37
Low
1.37
High
52 Week Price Range
0.25
Low
5.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Sharp Therapeutics Corp. (TSX‑V: SHRX.V) are limited; the company is listed on the TSX Venture Exchange and appears positioned as a therapeutics-focused issuer. Major long-term growth drivers are not well disclosed, though investors may benefit if the company advances clinical programs, secures partnerships or achieves clearer operational and financial transparency.

Principal risks include an uncertain or non-commercialized pipeline, small-cap liquidity and financing risk, and the regulatory and execution risks typical of early-stage biotech companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.37
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-512.77%
Net Debt
6.70M
ROCE
-117.79%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31
Type yearly yearly
Date 2024-12-31 2023-12-31
Income before tax -3.26M -3.56M
Net income -3.26M -3.56M
Selling general administrative 0.35M 0.43M
Reconciled depreciation 0.10M 0.11M
Operating income -4.55M -2.27M
Interest expense 0.17M 0.17M
Net interest income -0.17M -0.17M
Total revenue 0.00M 0.00M
Total operating expenses 4.55M 2.27M
Total other income expense net 1.46M -1.12M
Net income from continuing ops -3.26M -3.56M
Breakdown 2024-12-31 2023-12-31
Type yearly yearly
Date 2024-12-31 2023-12-31
Total assets 4.55M 1.55M
Total liab 1.97M 13.03M
Total stockholder equity 2.58M -11.48M
Other current liab 0.13M 1.39M
Capital stock 21.79M 4.55M
Retained earnings -19.89M -16.62M
Cash 3.48M 0.38M
Total current liabilities 0.69M 7.72M
Net debt - 6.70M
Short long term debt - 5.89M
Total current assets 3.52M 0.43M
Long term debt - 1.19M
Accounts payable 0.27M 0.18M
Non current assets total 1.04M 1.12M
Capital lease obligations 1.32M 1.34M
Breakdown 2024-12-31 2023-12-31
Type yearly yearly
Date 2024-12-31 2023-12-31
Net borrowings 1.76M -0.20M
Total cash from financing activities 6.73M 2.18M
Net income -3.26M -3.56M
Change in cash 3.10M 0.21M
Begin period cash flow 0.38M 0.16M
End period cash flow 3.48M 0.38M
Total cash from operating activities -3.62M -1.96M
Issuance of capital stock 4.96M 2.38M
Depreciation 0.10M 0.11M
Capital expenditures 0.01M 0.01M
Change in working capital 0.06M 0.16M
Stock based compensation 0.01M 0.03M
Other non cash items -0.79M 0.18M
Free cash flow -3.63M -1.97M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 -
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17
ARCH
Arch Biopartners Inc		 -0.03
3.41%		 0.85 - - 197.68 6211.54

Profile*

Sharp Therapeutics Corp.

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.

2403 Sidney Street, Pittsburgh, PA, United States, 15203

412 206 5303

https://www.sharptx.com

Name Title Year Born
Dr. Scott F. Sneddon J.D., Ph.D. CEO, Chief Science Officer & Director 1963
Mr. Edward Jonasson CA CPA Chief Financial Officer 1969
Mr. Lorne Michael Sugarman Independent Director & Corporate Secretary 1970
Mr. Marcel P. Bruchez Ph.D. Scientific Co-Founder & CTO NA
Dr. Alan S. Waggoner Ph.D. Scientific Co-Founder and Chief Architect NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…